| INTRODUCTION
The importance of reducing low-density lipoprotein cholesterol (LDL-C) to lower morbidity and mortality associated with cardiovascular disease is well established. Current guidelines recommend statins as first-line treatment for hypercholesterolemia in patients at high risk for cardiovascular mortality. [1] [2] [3] [4] [5] Despite the cholesterol-lowering effect of statins, a subset of patients may require additional LDL-C-lowering to reach risk-stratified LDL-C levels or to further reduce cardiovascular risk. 4, [6] [7] [8] [9] The development of monoclonal antibodies that bind proprotein convertase subtilisin/kexin type 9 (PCSK9) has allowed for additional highly effective treatment options for hypercholesterolemia.
Evolocumab is a human monoclonal antibody against PCSK9. The
Program to Reduce LDL-C and Cardiovascular Outcomes Following
Inhibition of PCSK9 In Different Populations (PROFICIO) is a comprehensive clinical trial program that established evolocumab efficacy and safety in diverse patient populations with hypercholesterolemia, including those with familial hypercholesterolemia or statin intolerance. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Within each of these studies, approved evolocumab dosing regimens have substantially and consistently reduced LDL-C.
To further elucidate the LDL-C lowering associated with each evolocumab dosing regimen for patient subsets defined by demographic and disease characteristics, we performed a pooled analysis to assess evolocumab efficacy compared to placebo or control from patients enrolled in four randomized placebo-or ezetimibe-controlled phase 3 trials.
| METHODS
Data were analyzed from patients enrolled in four randomized 12-week phase 3 evolocumab clinical trials (Table S1 , Supporting information). 13, [16] [17] [18] Background lipid therapies included statin alone or with ezetimibe. The evolocumab dosing regimens were 140 mg subcutaneously every 2 weeks (Q2W) and 420 mg monthly (QM) ( Table S1 ).
An ezetimibe treatment arm was included in three trials. 13, 17, 18 All patients provided written informed consent. The individual protocols were approved by each institutional review board and the investigations were in accordance with the Declaration of Helsinki. Additional methods for each trial have been reported elsewhere. 13, [16] [17] [18] Patient subgroups for the current analysis were defined according to baseline demographic and disease characteristics (Table 1) and were prespecified in the statistical analysis plans.
| Efficacy and safety endpoints
For this analysis, the primary outcome was the difference in percent change from baseline in LDL-C between each evolocumab dosing regimen and control using the mean of week 10 and 12 LDL-C values.
Key safety endpoints were treatment-emergent and serious adverse events (AEs), laboratory parameters, and anti-evolocumab antibodies.
| Statistical analysis
Data from 3146 patients who were randomized and received at least one dose of evolocumab or control were evaluated for efficacy and safety. Mean treatment effect differences and 95% confidence inter- Response was defined as a ≥ 15% LDL-C reduction at the mean of weeks 10 and 12; patients evaluable were those with an LDL-C value at that timepoint. No missing data imputation or multiplicity adjustments were performed. Baseline demographics, baseline lipid parameters, and safety data were assessed using descriptive statistics. All analyses were conducted with SAS/STAT, version 9.2 (SAS Institute, Cary, North Carolina). The studies were not powered for safety endpoints; therefore, no inferential statistical analyses with associated P values were conducted for adverse events.
3 | RESULTS
| Baseline characteristics
The patient populations of the evolocumab trials included in this analysis are summarized in Table S1 . 13, [16] [17] [18] 
| LDL-C reduction in overall population
In the individual studies, the mean percent change from baseline in (Table S3) .
Among all patients in this integrated population from all trials, mean percent changes from baseline in LDL-C were −65.7% (95% CI:
−70.9, −60.6; evolocumab 140 mg Q2W) and −65.0% (95% CI: 
| Safety
In the integrated population, the incidences of AEs and laboratory parameter elevations were similar across groups treated with each evolocumab dosing regimen or control. The rates of overall AEs were 43.8% (evolocumab 140 mg Q2W), 43.4% (evolocumab 420 mg QM), 48.8% (ezetimibe), and 41.8% (placebo) ( Table 2 ). Serious AEs occurred in 2.6%, 1.7%, 1.5%, and 2.3% of patients across the same groups, respectively. Muscle-related AEs were highest in the ezetimibe-treated group (7.8%) as compared to evolocumab 140 mg Q2W (3.5%), evolocumab 420 mg QM Potentially explanatory investigations into the cause of the observed numerical treatment effect in gender did not reveal alternative factors that could explain the results. In addition, P values were not adjusted for multiplicity; therefore, it is reasonable to suggest that the observed difference of treatment effect in gender was obtained by chance.
Results of the current study are consistent with those of a pooled analysis of phase 2 evolocumab studies. 21 That pooled analysis, which included 1359 patients from 4 studies, demonstrated similar reductions in LDL-C with evolocumab dosed at 140 mg Q2W or 420 mg the results of our current dataset is unknown. While this study was not designed to explore the biological and physiological pathways that underlie the gender differences in LDL-C reduction, it is hypothesisgenerating for additional mechanistic studies.
The safety profile revealed no new concerns. Together with efficacy data, these results support a favorable benefit-risk profile for evolocumab across diverse patient populations.
A strength of this analysis is that it includes a very diverse population with patients who had participated in monotherapy, statin combination therapy, statin intolerance, and heterozygous familial hypercholesterolemia evolocumab trials. The analysis also includes data from two dosing options, Q2W and QM, and from both placeboand ezetimibe-controlled trials. A limitation of our analysis is that this analysis was post hoc, with pooled data from four randomized studies.
| CONCLUSIONS
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